poisar

Stocks · News reference

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Aug 11, 2026, 2:28 PMBenzinga Newsdesk

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ORKA
Source
benzinga
Observed
Aug 11, 2026, 2:28 PM
Checked
Aug 11, 2026, 2:28 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 24, 2026, 8:06 PMSEC EDGAR

    8-K filing — Oruka Therapeutics, Inc. (ORKA)

    Filed: 2026-08-24 AccNo: 0001213900-26-093021 Size: 300 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    ORKA